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Abstract
Nicotine is a widely-abused drug, yet its primary reinforcing effect does not seem potent as other 
stimulants such as cocaine. Recent research on the contributing factors toward chronic use of 
nicotine-containing products has implicated the role of reinforcement-enhancing effects of 
nicotine. The present study investigates whether phencyclidine (PCP) may also possess a 
reinforcement-enhancement effect and how this may interact with the reinforcement-enhancement 
effect of nicotine. PCP was tested for two reasons: 1) it produces discrepant results on overall 
reward, similar to that seen with nicotine and 2) it may elucidate how other compounds may 
interact with the reinforcement-enhancement of nicotine. Adult male Sprague-Dawley rats were 
trained to lever press for brief visual stimulus presentations under fixed-ratio (FR) schedules of 
reinforcement and then were tested with nicotine (0.2 or 0.4 mg/kg) and/or PCP (2.0 mg/kg) over 
six increasing FR values. A selective increase in active lever-pressing for the visual stimulus with 
drug treatment was considered evidence of a reinforcement-enhancement effect. PCP and nicotine 
separately increased active lever pressing for a visual stimulus in a dose-dependent manner and 
across the different FR schedules. The addition of PCP to nicotine did not increase lever-pressing 
for the visual stimulus, possibly due to a ceiling effect. The effect of PCP may be driven largely 
by its locomotor stimulant effects, whereas the effect of nicotine was independent of locomotor 
stimulation. This dissociation emphasizes that distinct pharmacological properties contribute to the 
reinforcement-enhancement effects of substances.
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1. Introduction
Tobacco use is a costly and deadly health problem in the United States and globally. Every 
year, more Americans die from tobacco related disease than the total number of US 
casualties across the entirety of World War II (United States Department of Health and 
Human Services, 2014). Scientists generally agree that nicotine is the main constituent of 
tobacco to which users develop dependence (LaViolette & van der Kooy, 2004; United 
States Department of Health and Human Services, 1988; Karan et al., 2003; Rose, 2006). 
This agreement is notable in light of the growing literature suggesting that nicotine may 
have limited primary reinforcing effects (Donny et al., 2003; Chaudhri et al., 2006; Caggiula 
et al., 2009; Palmatier et al, 2006; Henningfield & Goldberg, 1983; Dougherty et al., 1981).
One possible mechanism that may bridge the gap between limited reinforcing effects and the 
prevalence of chronic tobacco use is the reward or reinforcement-enhancement effect of 
nicotine. For the smoker, this means that other reinforcers ongoing while smoking (i.e., self-
administering nicotine) may be more potent than when not smoking (see Caggiula et al., 
2009 for a review). In laboratory studies, this effect is shown by increased operant 
responding in rodents for a variety of rewards such as food (Barrett and Bevins, 2013; 
Palmatier et al., 2013) and visual stimuli (Donny et al., 2003; Barrett and Bevins, 2012) after 
nicotine exposure. In addition, this effect is not specific to non-human animals, as increased 
levels of responding for music has been shown in humans after nicotine exposure (Perkins 
and Karelitz, 2013). Importantly, this enhancement effect on operant responding by nicotine 
appears to be indicative of a change in the value of maintaining reinforcement, rather than 
the result of the locomotor stimulating properties of nicotine (cf. Donny et al., 2004; Barrett 
and Bevins, 2012; 2013).
This reinforcement-enhancement effect has been seen with a number of drugs other than 
nicotine; these include caffeine, amphetamine, cocaine, and pipradrol (Shepard et al., 2012; 
Hill, 1970; Phillips and Fibiger, 1990; Robbins and Koob, 1978; Beninger et al., 1980; 
1981). Notably, this effect has not been tested in phencyclidine (PCP). The importance of 
examining reinforcement-enhancement in PCP is twofold: 1) studies on the primary 
reinforcer value of phencyclidine have yielded discrepant results in rodents (Hillhouse et al., 
2014; Amitai et al., 2009; Kornetsky & Esposito, 1979; Carlezon & Wise, 1993, 1996; 
Collins et al., 1984; Lydall et al., 2010; Crider, 1986; Barr et al., 1985; Iwamoto, 1986) and 
2) PCP exposure is a commonly used preclinical model of positive, negative and cognitive 
symptoms of schizophrenia in rodents and schizophrenia has a particularly high incidence of 
comorbidity with nicotine dependence (Neill et al., 2010; Jones et al., 2011; Jentsch & Roth, 
1999; Kumari & Postma, 2005; Hughes et al., 1986; O’Farrell et al., 1983).
Nicotine and PCP share similarities with respect to abuse liability. Both are abused by 
humans although their primary reinforcing properties could be considered to be relatively 
weak. Though humans, primates and rodents will self-administer PCP, the rate of self-
administration is relatively low in comparison to other drugs of abuse such as opiates and 
stimulants (Newman et al., 2006, 2008; Crider, 1986; Balster & Woolverton, 1980; Carroll 
et al., 1981). Further, self-administration of PCP in rodents has also been particularly 
difficult to find (Collins et al., 1984). In other experimental situations, conclusions regarding 
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the overall rewarding effect of PCP have been mixed. Intracranial self-stimulation tasks 
have shown an increase and decrease in stimulation thresholds depending on the time point 
studied and measurement procedure, suggesting a decrease and increase in reward-related 
behavior, respectively (Amitai et al., 2009; Kornetsky & Esposito, 1979; Carlezon & Wise, 
1993, 1996). In addition, acute and chronic exposure to PCP in a sucrose-licking task found 
no effect on the total amount of sucrose consumed separate from motor confounds (Lydall et 
al., 2010). Given the abuse liability of PCP, the divergent findings with PCP on reward-
related behaviors suggest an additional mechanism might be important.
It is also unclear whether there is an interaction between the reinforcement-enhancement 
effect in nicotine and other drugs. Nicotine (in tobacco form) is widely used in conjunction 
with other drugs such as alcohol and cocaine (Grant el al., 2004; Epstein et al., 2010). 
Notably, rates of smoking are 2 to 4 times higher in patients with another substance-use 
disorder (Gulliver et al., 2005, 2000; Budney et al., 1993; Kalman et al., 2005). There has 
been little attention to how the reinforcement enhancement effects of nicotine interact with 
the effects of other drugs of abuse. To this end, the present study examined whether PCP 
shows a reinforcement-enhancement effect similar to that of nicotine and whether the 
combination interacts in a unique manner to alter reinforcer enhancement effects in rats. 
Lever-pressing for a visual stimulus was trained in drug-naïve rats and then tested after 
treatment with nicotine, PCP, or nicotine plus PCP. Previous studies in our lab using a 
similar procedure found robust differences between nicotine- and saline-treated rats (Barrett 
& Bevins, 2012; 2013). If PCP has a reinforcement-enhancement effect, we should observe 
selective increases in active-lever pressing maintained by visual stimuli, similar to that 
found with nicotine. If PCP alters the reinforcement-enhancement effect of nicotine, the rats 
that received the combination should differ from the nicotine alone and PCP alone groups. 
An increase would suggest a synergism (e.g., summative effect), whereas a decrease would 
suggest interference (e.g., antagonism).
2. Materials and methods
2.1 Subjects
Forty-eight adult male Sprague Dawley rats (226-250 g upon arrival, Charles River, Portage, 
MI) were used. One rat was unable to complete the study and was not included in the 
analysis. Rats were individually-housed in clear rectangular polycarbonate tubs (48.3 cm × 
26.7 cm × 20.3 cm) under 12-h light/dark conditions (light on between 6:30 am and 6:30 
pm). Room temperature was maintained at 22±1° C with a relative humidity of 45-60%. 
Water was continuously available in the home cage. Access to food was restricted to 
maintain rats at 90% of their free-feeding weight. After four weeks, the target weight was 
increased by 2 g. Animals were allowed 5 days of habituation to the animal facility before 
being used in experiments. During the final two days of this habituation period, each 
experimenter handled each rat for approximately 2.5 min per day. All experiments were 
performed during the light cycle and all procedures were approved by the Institutional 
Animal Care and Use Committee at the University of Nebraska-Lincoln.
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2.2 Drugs
Phencyclidine hydrochloride (PCP, received from the NIDA Chemical Synthesis and Drug 
Supply Program) was dissolved in 0.9% saline (w/v). (-)Nicotine tartrate salt (Sigma, St. 
Louis, MO) was dissolved in 0.9% saline and adjusted to a pH of 7.0 ± 0.2 with a dilute 
NaOH solution. Saline, nicotine, and PCP were all administered subcutaneously. Nicotine 
dose was based on previous research showing that 0.4 mg/kg nicotine produced a robust 
reinforcement-enhancement effect (Barrett & Bevins, 2012; 2013). The dose of PCP was 2.0 
mg/kg and was chosen based on pilot data suggesting that this dose would not significantly 
differ from other doses on locomotor activity or operant behavior measures and has been 
frequently used to produce psychoactive effects of PCP (Smith et al., 2011; Idris et al., 2005; 
Schreiber et al., 2000; Corbett et al., 1995; Jarbe et al., 1975; White & Holtzman, 1983). All 
drugs were administered at a volume of 1 ml/kg.
2.3 Apparatus
Sessions were conducted in eight conditioning chambers (ENV-008CT; Med Associates, 
Inc., St. Albans, VT; 30.5 × 24.1 × 21.0 cm, l × w × h) enclosed in light- and sound-
attenuating cubicles fitted with a fan used to mask noise and provide airflow. The sidewalls 
of the chambers were aluminum while the ceiling and front and back walls were clear 
polycarbonate. One sidewall featured a dipper receptacle, occupying a 5.2 × 5.2 × 3.8 cm (l 
× w × h) recessed space, into which a dipper arm when raised provided 0.1 ml of 26% 
sucrose solution (w/v) into the receptacle. Retractable levers were featured on either side of 
the dipper receptacle, approximately 5 cm from the chamber floor. White 28V DC lamps 
(100 mA) were located 3 cm above each lever, which will be referred to as cue lights. Two 
external 28V 100-mA DC lamps were also located above the chamber but within the sound 
attenuating cubicle, which will be referred to as the house light. An infrared emitter/detector 
unit positioned 4 cm above the rod floor bisected the chamber 14.5 cm from the sidewall 
featuring the dipper receptacle monitored general locomotor activity during experimental 
sessions. A computer running Med Associates interface and software (MedPC for Windows, 
IV) controlled stimulus presentations and recorded data.
2.4 Procedure
Lever-press training. All rats were first trained to lever-press maintained by sucrose in four 
consecutive sessions, approximately an hour in length. During these sessions, non-
contingent sucrose was available on a variable time (VT) schedule, starting with a VT 30 s 
on day one and fading to VT 180 s on the final day. Sucrose was also contingently available 
during these sessions on a fixed-ratio 1 (FR1) schedule by a lever-press on either the right or 
left lever. Both levers were presented initially and each lever-press resulted in a 4-sec 
presentation of sucrose followed by retraction of that lever and presentation of the opposite 
lever. This procedure ensured that rats received equal experience with reinforcement on both 
levers. The house light was illuminated throughout all lever-press training sessions and no 
cue lights were presented. To ensure all rats were lever-pressing at relatively high levels, 
there were 4 additional days of lever press training. During these additional days, the house 
light remained on and a randomly selected lever was inserted into the chamber. A lever-
press or a lapse of 15 sec resulted in a sucrose delivery, retraction of the lever, and a 20-
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second timeout. Following the timeout, a randomly selected lever was inserted into the 
chamber with the condition that the same lever was not presented more than twice in a row. 
The session ended after 60 sucrose deliveries (range = 65-80 min). One rat did not reach 
criterion (at least 80% of sucrose deliveries from lever-pressing) by the final day of training 
and was excluded from the study.
Lever-pressing for a visual reinforcer. For the first five days of this phase, rats were trained 
to lever-press for a visual stimulus on a variable ratio 2 schedule (VR2). The active lever 
was pseudo-randomly assigned for each rat. Completion of the VR2 resulted in 60 sec 
termination of the houselights with a concurrent illumination of the cue lights for the initial 
5 sec. Responses on the inactive lever produced no programmed consequence but were 
recorded. Lever-pressing during this training procedure was relatively low (mean +− SEM) 
and lever discrimination was not consistently at high levels of active to inactive pressing so 
all rats were switched to a FR1 schedule for the next ten days of training to ensure a stable 
baseline.
Drug testing. After 10 days of training, rats were pseudo-randomly assigned into one of six 
groups with the condition that lever-pressing did not differ between groups. The six groups 
(n= 7-8 per group) were based on the drugs administered before each testing session: SAL-
SAL, SAL-0.2N, SAL-0.4N, PCP-SAL, PCP-0.2N, or PCP-0.4N. On testing days, rats were 
injected with saline or PCP (2 mg/kg) 10 min before placement into the chamber. Rats were 
then injected with saline or nicotine (0.2 or 0.4 mg/kg) 5 min before placement in the 
chamber. Rats were allowed to lever press for visual stimuli arranged on a fixed ratio 
schedule over 60-min sessions, as described earlier. The FR schedule of visual-stimulus 
reinforcement increased over blocks of five sessions according to the following sequence: 
FR1, FR2, FR4, FR8, FR16, and FR32.
After thirty days of testing, all rats were left undisturbed in their home cages for seven days 
before undergoing four challenge days. During the challenge days, rats were tested on an 
FR2 schedule as reliable differences between groups were seen on this reinforcement 
schedule during the previous testing phase. For the first three days, all rats, regardless of 
group, were challenged with saline, 0.2 mg/kg nicotine, or 0.4 mg/kg nicotine in a 
counterbalanced fashion. After each challenge day, rats had one full day in their home cage 
to minimize potential carryover effects. Finally, two weeks later the fourth and final 
challenge of PCP (2 mg/kg) was given to all rats.
2.5 Dependent Measures and Statistical Analyses
The primary dependent measures throughout the experiment were number of lever presses 
on the active or inactive lever and the number of breaks of chamber infrared beam (i.e., 
activity). Data across the nicotine and PCP administration sessions of the escalating FR 
schedule were analyzed using targeted mixed-factor analyses of variance (ANOVA) with 
Group and FR Schedule as between- and within-subjects factors, respectively. For the 
nicotine and PCP challenge tests, one-way ANOVAs across groups were conducted. To 
reduce the risk of Type I and Type II errors, we conducted separate ANOVAs to evaluate 
the effects of nicotine in the absence of PCP (SAL-SAL vs SAL-0.2N vs SAL-0.4N), the 
effects of PCP in the absence of nicotine (SAL-SAL vs PCP-SAL), and the effects of PCP 
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on each dose of nicotine (SAL-0.2N vs PCP-0.2N and SAL-0.4N vs PCP-0.4N). Mauchly’s 
test of sphericity (1940) was included as part of the ANOVAs; when sphericity was violated, 
Greenhouse-Geisser corrections was employed to determine significant main effects and 
interactions. Post-hoc pairwise comparisons were made using Fisher’s Least Significant 
Difference (LSD) test and are reported as LSD minimum mean differences. A conventional 
alpha value of less than 0.05 was used to determine statistical significance.
3 Results
3.1 Nicotine on Active Lever- Pressing
Figure 1A portrays the effects of administration of 0.2 or 0.4 mg/kg nicotine on active lever 
pressing as a function of FR schedule (groups SAL-SAL, SAL-0.2N and SAL-0.4N). 
Nicotine dose-dependently increased active lever pressing and this effect appeared enhanced 
with increases in FR schedule. Three factor, mixed factors ANOVA revealed significant 
main effects of Group [F(2,20)=5.34; p=0.014] and Schedule [F(5,100)=6.89; p=0.005], as 
well as a significant Group × Schedule interaction [F(10,100)=3.64; p=0.020]. Post-hoc 
comparisons revealed that active lever pressing in the SAL-0.2N was significantly higher 
than SAL-SAL on schedules FR4 through FR32 [LSD =25.0]. Active lever pressing in the 
SAL-0.4N group was significantly higher than the SAL-SAL group across all FR schedules 
[LSD =25.0]. Active lever pressing was significantly higher in the SAL-0.4N group 
compared to the SAL-0.2N group on schedules FR8 through FR32. Changes in FR schedule 
produced no significant effects on active lever pressing in the SAL-SAL group. In the 
SAL-0.2N group, active lever pressing was higher on schedules FR8 and FR16 compared to 
FR1, and FR8 responding also differed from FR2. In the SAL-0.4N group, active lever 
pressing on schedules FR8 through FR32 was higher than on FR1 through FR4; responding 
on FR4 was also higher than responding on FR1.
3.2 Nicotine on Inactive Lever-Pressing
Figure 1B depicts the effects on nicotine administration on inactive lever pressing across FR 
schedules. Both doses on nicotine increased inactive lever pressing, but this effect did not 
vary systematically with FR schedule. Analysis revealed a significant main effect of Group 
[F(2,20)=3.83; p=0.039], but not of Schedule [F(5,100)=2.25; p=0.102]. A significant Group 
× Schedule interaction was also detected [F(10,100)=3.26; p=0.012]. Post-hoc comparisons 
revealed significantly higher inactive lever pressing in the SAL-0.2N and SAL-0.4N groups 
compared to SAL-SAL across all FR schedules [LSD =4.63]. Additionally, inactive lever 
pressing was significantly higher in the SAL-0.4N group compared to SAL-0.2N on FR16 
and FR32.
3.3 Nicotine on Activity
The effects of nicotine administration on locomotor activity are shown in Figure 1C. 
Nicotine at either dose increased locomotor activity above saline, though this effect did not 
vary with FR schedule. Analysis of the data revealed a significant main effect of Group 
[F(2.20)=15.9; p<0.001], but not of Schedule and no Group × Schedule interaction 
[Fs≤2.60; ps≥0.091]. Post-hoc comparisons on the effect of Group revealed that groups 
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SAL-0.2N and SAL-0.4N exhibited higher activity compare to SAL-SAL, but did not differ 
significantly from each other [LSD =242].
3.4 PCP on Lever-Pressing
The panels of Figure 2 depict the effects of PCP administered alone on lever pressing and 
locomotor activity as a function of FR schedule. PCP increased active lever pressing above 
saline levels. There was a tendency for this effect to increase with FR schedule (Figure 2A). 
The omnibus ANOVA revealed a significant main effect of Group [F(1,14)=6.53; p=0.023]. 
The main effect of Schedule [F(5,70)=1.74; p=0.206] and the Group × Schedule interaction 
[F(5,70)=2.20; p=0.153] were not significant. PCP also increased inactive lever pressing 
above saline levels, but this effect did not vary systematically with FR schedule (Figure 2B). 
The ANOVA revealed a significant effect of Group [F(1,14)=6.05; p=0.027], but no main 
effect of Schedule [F(5,70)=1.05; p=0.353] or Group × Schedule interaction [F(5,70)=1.82; 
p=0.189]. Finally, PCP increased locomotor activity relative to saline and this effect was 
also insensitive to changes in FR schedule (Figure 2C). Analysis revealed a significant effect 
of Group [F(1,14)=28.8; p<0.001], but no main effect Schedule or Group × Schedule 
interaction [Fs≤1.01; ps≥0.343].
3.5 Interaction of 0.2 mg/kg Nicotine and PCP
The interaction of PCP administration with the behavioral effects of 0.2 mg/kg nicotine is 
shown in the panels of Figure 3. Active lever pressing in the PCP-0.2N group was elevated 
above that of the SAL-0.2N group across FR schedules (Figure 3A). Statistical analysis 
revealed significant main effects of Group [F(1,13)=5.26; p=0.039] and of Schedule 
[F(5,65)=4.36; p=0.019]; the Group × Schedule interaction was not significant [F<1]. Post-
hoc comparisons on the main effect of Schedule found significantly higher responding on 
schedules FR4 through FR32 compared to FR1 [LSD =20.2]. Inactive lever pressing was 
also higher in the PCP-0.2N group than the SAL-0.2N group across FR schedules (Figure 
3B). The ANOVA revealed a significant main effect of Group [F(1,13)=8.57; p=0.012]. 
There was no main effect of Schedule or Group × Schedule interaction [Fs≤1.24; ps≥0.30]. 
Finally, although rats in the PCP-0.2N group exhibited a tendency for greater locomotor 
stimulation that those of the SAL-0.2N group, this effect was not significant (Figure 3C; 
[Fs<1.09; ps>0.315]).
3.6 Interaction of 0.4 mg/kg Nicotine and PCP
The effects of 0.4 mg/kg nicotine administered after saline or PCP are portrayed in the 
panels of Figure 4. In the PCP-0.4N and SAL-0.4N groups, active lever pressing increased 
as a function of FR schedule, with a tendency for higher responding in the PCP-0.4N group 
(Figure 4A). However, statistical analysis revealed only a main effect on Schedule 
[F(5,70)=8.78; p=0.005]; there was no main effect of Group or an interaction [Fs≤2.89; 
ps≥0.111]. Follow-up pairwise comparisons on the effect of Schedule found significantly 
higher responding on FR16 and FR32 compared to schedules FR1 through FR4, and 
significantly higher responding on FR8 compared to FR1 [LSD =41.7]. Inactive lever 
pressing had a tendency to be higher in the PCP-0.4N group (Figure 4B), but the main 
effects and interaction were not statistically significant [Fs≤2.81; ps≥0.116]. Likewise, 
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analysis of the locomotor data (Figure 4C) found no effects of Group or Schedule, and no 
interaction [Fs≤2.67; ps≥0.124].
3.7 Effects of PCP on Nicotine Dose Effect
An analysis of the effects of Group and Schedule between the PCP-SAL, PCP-0.2N and 
PCP-0.4N groups reveals no significant Group main effect or Group × Schedule interaction 
[Fs≤2.36; ps≥0.119]. There was a significant main effect of Schedule [F(5,105)=7.12; 
p=0.006].
3.8 Demand Analysis
To determine whether an alternative measure of reinforcement value would corroborate our 
findings with lever-pressing rates, we fit the reinforcer demand model (Hursh and 
Silberberg, 2008) to the data in the present experiment, and conducted two-factor ANOVAs 
on the model estimate of “essential value” (α) with Nicotine and PCP conditions as 
between-subject factors. Analyses revealed that nicotine significantly enhanced “essential 
value” of VS presentation as a reinforcer [F(2,39)=3.78; p=0.032] while PCP had no effect 
and there was no interaction between Nicotine and PCP conditions [Fs≤2.39; ps≥0.130].
3.9 Challenge Days
Analyses of the challenge test data found no significant effects of Group on active lever-
pressing, inactive lever-pressing, or activity following challenge with 0.2 mg/kg nicotine, 
0.4 mg/kg nicotine, or 2 mg/kg PCP [Fs≤3.62; ps≥0.078]. That is, none of the groups 
differed from each other in responsiveness to PCP or either dose of nicotine despite their 
differential histories with nicotine and PCP.
4. Discussion
The current study was designed to determine whether PCP had a reinforcement-
enhancement effect on responding for a visual stimulus similar to that reported for nicotine. 
We also assessed the potential interaction between PCP and nicotine on operant responding 
for a visual stimulus. PCP and nicotine increased active lever presses for a visual stimulus in 
comparison to saline controls and this effect was sustained as the FR schedule increased to 
an FR32. Interestingly, PCP further enhanced responding when given with a low dose of 
nicotine (0.2 mg/kg). This effect was dose-dependent, as the combination of PCP and the 
high dose of nicotine did not change responding.
One notable finding from this study is that PCP increased active lever-pressing for a visual 
stimulus. We also found that nicotine, at both doses, and PCP increased rates of general 
locomotor activity but only when compared to rats that only received saline (i.e., SAL-
SAL). That is, both drugs produced locomotor activation, but the combination of nicotine 
and PCP administration had no detectable additive effects on general activity. While the 
effects of nicotine and PCP are parallel for general activity, PCP also increased rates of 
inactive lever pressing as a function of FR Schedule, while nicotine did not. Put simply, PCP 
enhanced levels of general activity and lever pressing irrespective of lever, whereas nicotine 
enhanced general activity and lever pressing specific to the active lever. In a similar vein, 
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PCP did not show an increase of active lever pressing across FR values, which would be 
expected given that an increasing number of lever presses are required for each presentation 
of the visual stimulus. Combined, the present findings suggest that while both nicotine and 
PCP increase levels of operant responding for sensory stimuli, the effect of nicotine reflect 
an enhancement of the reward value of the visual stimulus, whereas the effect of PCP 
appears to be driven more by motor stimulation. There are many ways that changes in 
reinforcement value can be assessed; of which response rates on ratio-based schedules of 
reinforcement is one approach. Previous work from our laboratory (Barrett and Bevins, 
2012) and that of Dallery and colleagues (Cassidy and Dallery, 2012) have demonstrated 
how the application of behavioral economic modeling provides a power method for the 
quantitative assessment of the value-altering effects of nicotine. Briefly, by fitting the 
reinforcer demand model proposed by Hursh and Silberberg (2008) to the data of 
individuals, one can quantifiably estimate the “essential value” of a reinforcer under 
different conditions as a reflection of sensitivity of individuals toward defending levels of 
reinforcer consumption (i.e., number of VS presentations earned) in the face of increasing 
response cost (i.e. FR schedule). Such an analysis here revealed that nicotine increased the 
essential value measure, whereas there was no effect of PCP. This demand analysis supports 
the earlier conclusion that nicotine enhanced the value of the VS reinforcer in the present 
study, yet PCP under the conditions of this study had no effect on reinforcement value.
The effects of PCP alone on this measure are somewhat surprising given previous work on 
the effects of PCP on reward. Pre-treatment with PCP produces a threshold increase in 
intracranial self-stimulation. However, this effect was attenuated and ultimately reversed 
after repeated PCP treatment, suggesting that initial PCP exposure produced an anhedonic-
like effect which eventually dissipates and even leads to increased reward functioning 
(Amitai et al., 2009). This conversion from deficit to reward has been seen in the place 
conditioning procedures as well, with the initial conditioned place aversion switching to a 
conditioned place preference after repeated treatment (Kitaichi et al., 1996). In addition, 
PCP at the dose used in this work (2.0 mg/kg) in the 5-CSRTT paradigm produced initial 
non-specific response-depressant effects (Amitai et al., 2007). However, in the present task, 
PCP produced an increase in lever-pressing on all FR schedules, beginning on the 1st day. 
The lack of the similar effects in these behavioral tasks is somewhat puzzling but could 
reflect the inherent differences between operant responding for a visual stimulus and the 
more cognitively-focused 5-CSRTT task. Either way, further examination of the influences 
of PCP on measures of reinforcement value could be illuminating, especially by utilizing a 
procedure less susceptible to being influenced by alterations in activity.
Co-administration of PCP and nicotine increased lever-pressing relative to the nicotine-
alone groups, suggesting that there may be an interaction between these two drugs. The 
increase in responding for the PCP-0.2N group may be due to an additive influence of PCP-
induced hyperlocomotion combined with the reinforcement-enhancement effect of nicotine. 
This interpretation is supported by the lack of interactions between group and schedule as 
well as the lack of change in responding over FR values. In addition, a combined analysis 
showed that active lever-pressing in the PCP-SAL group did not vary significantly with 
changes in FR schedule, but the addition of 0.2 or 0.4 mg/kg nicotine in the PCP-0.2N and 
PCP-0.4N groups resulted in significant effects of FR schedule in both of these groups.
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A potential limitation of this study is the use of a single dose of PCP. It may be possible that 
the lack of a reinforcement-enhancement effect seen in this study is specific only to the dose 
used. However, this is relatively unlikely. Preliminary data showed no main effect between 
this dose of PCP and two other doses (PCP 1.0 mg/kg and PCP 3.0 mg/kg) over 5 days of 
lever-pressing on an FR1 for a visual stimulus. In addition, higher doses of PCP (2.5 mg/kg 
and higher) have shown to significantly decrease operant behavior over a number of 
schedules (Gilmour et al., 2009).
PCP increased lever-pressing for a visual stimulus similar to that seen with nicotine and co-
administration of PCP and low dose nicotine led to an increase in lever-pressing over 
nicotine alone. However, in comparison to the reinforcement-enhancement effect of 
nicotine, the reinforcement-enhancement effect of PCP seems to be primarily controlled by 
the locomotor potentiation effect of PCP. In addition, the interaction effect seems to be 
driven by the effects of PCP, which again could be due to its locomotor effects. Further 
exploration of the reinforcement-enhancement effect of PCP is warranted, specifically in a 
model of reinforcement-enhancement that may not be as influenced by differences in 
activity. The interaction of PCP as well as other drugs and the reinforcement-enhancement 
effect could provide valuable information on the comorbidity of nicotine use and other 
substances.
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Highlights
▶ PCP increased lever-pressing for a visual stimulus.
▶ Two doses of nicotine increased lever-pressing for a visual stimulus.
▶ The combination of PCP and nicotine did not increase lever-pressing.
▶ The effect of PCP on lever-pressing may be due to motor activation.
Swalve et al. Page 14
Behav Brain Res. Author manuscript; available in PMC 2016 September 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 1. 
Panel A displays active lever pressing for visual stimulation as a function of FR schedule in 
animals treated with saline alone or either dose of nicotine. Panel B shows inactive lever-
pressing and Panel C shows overall activity as measured by locomotor beam breaks for the 
same groups. Data is expressed as the mean (± SEM) over the terminal three sessions of 
each 5 session FR schedule block.
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Figure 2. 
Panel A displays active lever pressing for visual stimulation as a function of FR schedule 
comparing animals treated with PCP to animals treated with saline. Panel B shows inactive 
lever-pressing and Panel C shows overall activity as measured by locomotor beam breaks 
for the same groups.
Swalve et al. Page 16
Behav Brain Res. Author manuscript; available in PMC 2016 September 15.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 3. 
Panel A displays active lever pressing for visual stimulation as a function of FR schedule 
comparing animals treated with PCP and NIC 0.2 mg/kg to animals treated with NIC 0.2 
mg/kg. Panel B shows inactive lever-pressing and Panel C shows overall activity as 
measured by locomotor beam breaks for the same groups.
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Figure 4. 
Panel A displays active lever pressing for visual stimulation as a function of FR schedule 
comparing animals treated with PCP and NIC 0.4 mg/kg to animals treated with NIC 0.4 
mg/kg. Panel B shows inactive lever-pressing and Panel C shows overall activity as 
measured by locomotor beam breaks for the same groups.
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